Schedule of Investments | |||||||
March 31, 2023 (unaudited) | |||||||
AmericaFirst Defensive Growth Fund | |||||||
Shares or Principal | |||||||
Security Description |
|
| Amount ($) |
| Fair Value ($)(1) | ||
| |||||||
Common Stocks - 90.07% | |||||||
Beverages - 3.59% | |||||||
Keurig Dr. Pepper, Inc. | 1497 | 52,814 | |||||
Biological Products (No Diagnostic Substances) - 7.18% | |||||||
Biogen, Inc. (2) | 188 | 52,270 | |||||
Gilead Sciences, Inc. | 641 | 53,184 | |||||
105,454 | |||||||
Cigarettes - 3.47% | |||||||
Philip Morris International, Inc. | 523 | 50,862 | |||||
Electric & Other Services Combined - 7.47% | |||||||
WEC Energy Group, Inc. | 585 | 55,452 | |||||
Xcel Energy, Inc. | 804 | 54,222 | |||||
109,674 | |||||||
Electric Services - 3.90% | |||||||
The Southern Co. | 823 | 57,264 | |||||
Fats & Oils - 3.50% | |||||||
Archer-Daniels Midland Co. | 644 | 51,301 | |||||
Food & Kindred Products - 3.78% | |||||||
Mondelez International, Inc. Class A (2) | 795 | 55,427 | |||||
Grain Mill Products - 3.80% | |||||||
General Mills, Inc. | 652 | 55,720 | |||||
Hospital & Medical Service Plans - 10.06% | |||||||
Centene Corp. (2) | 745 | 47,092 | |||||
Elevance Health, Inc. | 110 | 50,579 | |||||
Humana, Inc. | 103 | 50,002 | |||||
147,673 | |||||||
Perfumes, Cosmetics & Other Toilet Preparations - 3.48% | |||||||
The Estee Lauder Cos., Inc. Class A (2) | 207 | 51,017 | |||||
Pharmaceutical Preparations - 25.52% | |||||||
Abbott Laboratories (2) | 507 | 51,339 | |||||
Bristol-Myers Squibb Co. | 734 | 50,874 | |||||
Eli Lilly & Co. (2) | 162 | 55,634 | |||||
Johnson & Johnson | 335 | 51,925 | |||||
Moderna, Inc. (2) | 375 | 57,593 | |||||
Pfizer, Inc. | 1,260 | 51,408 | |||||
Vertex Pharmaceuticals, Inc. (2) | 177 | 55,767 | |||||
374,540 | |||||||
Retail-Drug Stores and Proprietary Stores - 3.13% | |||||||
CVS Health Corp. | 619 | 45,998 | |||||
Services-Prepackaged Software - 3.86% | |||||||
Veeva Systems, Inc. Class A (2) | 308 | 56,607 | |||||
Sugar & Confectionery Products - 3.76% | |||||||
The Hershey Co. (2) | 217 | 55,207 | |||||
Wholesale-Drugs Proprietaries & Druggists' Sundries - 3.57% | |||||||
McKesson Corp. (2) | 147 | 52,339 | |||||
Total Common Stock | (Cost $ 1,351,758) | 1,321,897 | |||||
Exchange Traded Funds - 9.27% | |||||||
ProShares Short S&P 500 ETF (3) | 9,066 | 135,990 | |||||
Total Exchange Traded Funds | (Cost $ 137,873) | 135,990 | |||||
Money Market Registered Investment Companies - 0.25% | |||||||
Federated Hermes Institutional Prime Obligations Fund - Institutional Class, 4.85% (4) | 3,607 | 3,607 | |||||
Total Money Market Registered Investment Companies | (Cost $ 3,607) | 3,607 | |||||
Total Investments - 99.59% | (Cost $ 1,493,238) | 1,461,494 | |||||
Other Assets Less Liabilities - .41% | 6,081 | ||||||
Total Net Assets - 100.00% | 1,467,575 | ||||||
(1) Statement on Financial Accounting Standard No. 157 "Fair Value Measurements" - Various inputs are used in determining the value of the Fund's investments. | |||||||
These inputs are summarized in the three broad levels listed below. | |||||||
• Level 1 - quoted prices in active markets for identical securities | |||||||
• Level 2 - other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.) | |||||||
• Level 3 - significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments) | |||||||
The following is a summary of the inputs used as of March 31, 2023 in valuing the Fund's assets carried at fair value: | |||||||
|
|
|
|
| Investments in |
| Other Financial |
Valuation Inputs |
|
|
| Securities |
| Instruments (3) | |
Level 1 - Quoted Prices |
|
| $ | 1,461,494 | $ | - | |
Level 2 - Other Significant Observable Inputs |
|
|
|
| - | ||
Level 3 - Significant Unobservable Inputs |
|
| - |
| - | ||
Total |
|
|
| $ | 1,461,494 | $ | 0 |
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. For example, short-term | |||||||
debt instruments and repurchase agreements with a maturity of less than 60 days are valued using amortized cost, in accordance with rules under the Investment | |||||||
Company Act of 1940. Generally, amortized cost approximates the current fair value of a security, but since the value is not obtained from a quoted price in an active | |||||||
market, such securities are reflected as Level 2. | |||||||
(2) Represents non-income producing securities. | |||||||
(3) Exchange-traded fund. | |||||||
(4) Investment in affiliate. The yield shown represents the 7-day yield in effect at March 31, 2023. |
- Company Dashboard
- Filings
-
NPORT-P Filing
Americafirst Quantitative Funds NPORT-PAmericaFirst Defensive Growth Fund (Mar 2023 report)
Filed: 8 May 23, 12:37pm